Day: May 29, 2024

NORWALK, Conn., May 29, 2024 (GLOBE NEWSWIRE) — Reed’s, Inc. (OTCQX: REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, natural ginger beverages, today announced the launch of Virgil’s full sugar handcrafted sodas in a new, convenient 12oz can format for five classic flavors in Sprouts Farmers Market nationwide. “We’re thrilled to unveil Virgil’s handcrafted sodas in a convenient, easy-to-carry 12oz can format, catering to consumer preferences and the rising demand for on-the-go beverages,” said Norman E. Snyder, Jr., CEO of Reed’s. “Our classic flavors, previously available only in bottles, are now more accessible than ever, allowing our customers to enjoy Virgil’s premium sodas wherever they go. We’re initially launching the new can format in Sprout’s nationwide and look forward...

 Battery Testing and Analysis Services Unit to Generate $8 Million to $10 Million Revenue Annually Starting in 2025 SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), a global leader in sustainable energy management, today announced it has secured a contract from a top Japanese multinational automaker (“Automaker”) for testing and analysis of high-energy battery cells intended for their next-generation electric vehicles. The Company will utilize its KULR ONE Design Solutions (K1-DS) platform to expedite design readiness for the Automaker’s future electric vehicle buildout. KULR’s extensive spaceflight expertise and proprietary KULR ONE Design Solutions are integrated into its rigorous testing protocols, forming what KULR believes to be the world’s most comprehensive...

ART12.11 demonstrates comparable pharmacokinetics compared to Epidiolex® SOLANA BEACH, Calif., May 29, 2024 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced Dr. Andrew Yates presented new pre-clinical data on ART12.11 at the CT-CANN24 conference which is being held May 29-30, 2024 at the Hilton London Canary Wharf in London, UK. The presentation, titled “An Aqueous Suspension of a Novel Cannabidiol: Tetramethylpyrazine Co-crystal, demonstrates a pharmacokinetic profile comparable with Epidiolex® in Rats,” highlights the Company’s patented cocrystal of CBD and TMP (tetramethylpyrazine), ART12.11, in an unoptimized formulation,...

IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) — Rivian (NASDAQ: RIVN), has today announced that at 8.00am EDT on May 30, 2024, its Founder and CEO RJ Scaringe will participate in a fireside chat at Bernstein’s 40th Annual Strategic Decisions Conference. A live webcast of the fireside chat will be available here. Investor Contact:ir@rivian.com Media Contact:Harry Porter: media@rivian.com About Rivian:Rivian (NASDAQ: RIVN) is an American automotive manufacturer that develops and builds category-defining electric vehicles and accessories. The company creates innovative and technologically advanced products that are designed to excel at work and play with the goal of accelerating the global transition to zero-emission transportation and energy. Rivian vehicles are built in the United States and are sold directly to consumer and commercial...

Due to increased costs Nordea Abp will adjust the Base Rate Margin (which in previous base prospectuses also has been referred to as “räntebasmarginal ”) for Nordea branded bull and bear certificates. The relevant Base Rates may either be decreased or increased on isin level, but the adjustments will in general consist of fee increases. The fee adjustments will be effective from the 14th of June 2024. All affected instruments will be traded just as any other trading day both until and after that date. Affected instruments can be found in the pdf.AttachmentAffected instruments

ST. LOUIS, May 29, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announces the successful treatment of the first heart rhythm patients by Penn Presbyterian Medical Center (PPMC) utilizing the advanced Genesis Robotic Magnetic Navigation System. PPMC, part of the University of Pennsylvania Health System, renowned for advanced clinical research, innovation, and compassionate patient care, stands at the forefront as the first in the Northeast United States to offer the Genesis System. Genesis is the latest advancement in Robotic Magnetic Navigation technology. Robotic Magnetic Navigation introduces the benefits of robotic precision and safety to cardiac ablation, a common minimally invasive procedure to treat arrhythmias. Tens of millions of...

(UPM, Helsinki, 29 May 2024 at 15:20 EEST) – UPM Communication Papers plans to permanently close its Hürth newsprint mill and to shut down one fine paper machine at Nordland Papier (PM 3) in Dörpen, both assets located in Germany. If realized, the measures would result in annual reductions of 330,000 tonnes of newsprint paper capacity and 280,000 tonnes of uncoated fine paper capacity in UPM’s portfolio. These plans are a continuation of necessary steps to proactively align with customer demand and ensure competitiveness. Should the plans be implemented the number of positions affected is estimated approximately at 135 in Hürth and 210 in Dörpen. The participation process with the workers council will start immediately in line with local legislation. Both paper machines affected by the planned measure would stop graphic paper production...

Glen Rock, N.J., May 29, 2024 (GLOBE NEWSWIRE) — RespireRx Pharmaceuticals Inc. (OTC Pink Markets: RSPI) (RespireRx or the Company), focused on the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is delighted to announce that the Department of Defense (DOD) has approved a $1.8 million translational research award to Shirley Ryan AbilityLab to fund a two stage Phase 2A and 2B clinical study in order to determine the safety and efficacy of CX1739, its lead clinical AMPAkine, to improve bladder function and motor activity in individuals with spinal cord injury (SCI). This grant award supports the ongoing collaboration among scientist teams led by Milap Sandhu, PT, PhD, research scientist at Shirley Ryan AbilityLab, a rehabilitation research hospital...